Clinical trials: Steatohepatitis, Nonalcoholic
Nonalcoholic Steatohepatitis (NASH)
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of CS0159 in Subjects With NASH
A randomized, double-blind study to assess the safety, tolerability, PK and efficacy of CS0159 in subjects with Non-Alcoholic Steatohepatitis (NASH)
- Trial name
- NCT05591079
- Testing
- CS0159 (Linafexor)
- Where
- 17 sites in United States
- Volunteers
- 99 people
- Sponsor
- Cascade Pharmaceuticals, Inc
Metabolic Dysfunction-associated Fatty Liver Disease
The Potential Value and Impact of Diagnostic Biomarkers for MAFLD Using Machine Learning Methods
This is a case-control study that aims to build a predictive model for MAFLD based on machine learning.
- Trial name
- NCT06061640
- Where
- China
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- The First Affiliated Hospital of Zhejiang Chinese Medical University
Liver Diseases
Effect of Non-alcoholic Fatty Liver Disease on Kidney Functions
Non-alcoholic fatty liver disease is the most common cause of chronic liver disease worldwide. It is defined as the accumulation of fat (>5%) in the liver cells in the absence of excessive alcohol intake or other causes of liver…
- Trial name
- NCT03172650
- Testing
- glomerular filtration rate
- Where
- Egypt
- Volunteers
- 120 people
- Sponsor
- Assiut University
Nonalcoholic Steatohepatitis
Efficacy and Safety of Viusid in Patients With Nonalcoholic Steatohepatitis
The purpose of the study is to evaluate whether Viusid, a nutritional supplement, in combination with diet and exercise improve the histological results (steatosis, necro-inflammatory activity and fibrosis) in comparison with…
- Trial name
- NCT00509418
- Testing
- Viusid, Hypocaloric Diet with controlled exercise
- Where
- Cuba
- Volunteers
- 60 people
- Sponsor
- Catalysis SL
NAFLD
Impact of NAFLD vs MAFLD Stigma on Quality of Life in Egyptian Patients
Non-alcoholic fatty liver disease (NAFLD) has become the leading cause of liver disease worldwide. The global burden of NAFLD is about 30% of the population, With a higher prevalence in Egypt about 47.5 %.
- Trial name
- NCT06503068
- Testing
- Questionnaire
- Where
- Egypt
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Tanta University
Nonalcoholic Steatohepatitis (NASH)
Study to Evaluate the Safety, Tolerability, and Efficacy of ASC41 in Adults With NASH
This is a phase 2, randomized, double-blind, placebo controlled study in adults with biopsy confirmed NASH. The study is aimed at evaluating efficacy and tolerability of ASC41 in adults with NASH.
- Trial name
- NCT05118360
- Testing
- ASC41 2 mg, ASC41 4 mg
- Sponsor
- Gannex Pharma Co., Ltd.
Morbid Obesity, Obstructive Sleep Apnea Syndrome
LAGB as a Treatment for Morbid Obesity in Adolescents
Laparoscopic adjustable gastric banding (LAGB) has been used worldwide to help selected morbidly obese adults to lose weight. The FDA has approved LAGB only for patients 18 years or older.
- Conditions
- Morbid Obesity, Obstructive Sleep Apnea Syndrome, Metabolic Syndrome, Insulin Resistance
- Trial name
- NCT01045499
- Testing
- Laparoscopic adjustable gastric banding (Allergan Lap Band)
- Where
- United States
- Volunteers
- 137 people
- Sponsor
- Jeffrey L Zitsman, MD
Non Alcoholic Steatohepatitis
Expanding Donor Pool for Live Donor Liver Transplantation: Utilization of Donors With NASH After Optimization
Live donor liver transplantation (LDLT) is the treatment of choice for end-stage liver disease, predominantly in the East, where deceased donor liver transplantation is sparse.
- Trial name
- NCT04571957
- Testing
- No Intervention
- Where
- India
- Volunteers
- 410 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Fatty Liver
Non Alcoholic Fatty Liver Disease (NAFLD) in Hong Kong
The true incidence and prevalence of NAFLD in Hong Kong has not been determined. The natural history of NAFLD is not well defined partly because of differences in the exclusion limit of alcohol and the required histological…
- Trial name
- NCT00577044
- Where
- 5 sites in China
- Volunteers
- 600 people
- Sponsor
- Hospital Authority, Hong Kong
Nonalcoholic Fatty Liver Disease
Abundance and Distribution of Lipids and Proteins in Nonalcoholic Fatty Liver Disease (NAFLD)
Nonalcoholic fatty liver disease (NAFLD) is the most common type of liver disease in the United States. The incidence of NAFLD is very similar to that of obesity, type 2 diabetes, and the metabolic syndrome.
- Trial name
- NCT00983463
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Vanderbilt University
Non Alcoholic Steatohepatitis (NASH)
A Phase 2b Study of Icosabutate in Fatty Liver Disease
A Phase 2b study to evaluate the efficacy of different doses of NST-4016 on the resolution of NASH without worsening of fibrosis
- Trial name
- ICONA (NCT04052516)
- Testing
- Icosabutate
- Where
- 39 sites in United States, Puerto Rico
- Volunteers
- 280 people
- Sponsor
- NorthSea Therapeutics B.V.
NASH - Nonalcoholic Steatohepatitis
A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )
This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver fibrosis histological stage F2 or F3
- Trial name
- NATiV3 (NCT04849728)
- Testing
- IVA337
- Where
- 459 sites in United States, Argentina and 22 more
- Volunteers
- 1,000 people
- Sponsor
- Inventiva Pharma
Fatty Liver, NAFLD
Impact of Exercise Intervention for Patients With Non-alcoholic Fatty Liver Disease
In Taiwan, with the westernization of eating habit and lifestyle, metabolic syndrome and non-alcoholic fatty liver (NAFLD) have become very important health issues.
- Trial name
- NAFLD (NCT04463667)
- Testing
- exercise
- Where
- Taiwan
- Volunteers
- 100 people
- Sponsor
- National Taiwan University Hospital
NAFLD, Overweight and Obesity
The Role of Dietary Carbohydrate and Fat Availability in the Regulation of Hepatic Lipid Content
The purpose of this study is to investigate dietary compositions effect on liverfat measured by magnetic resonance imaging.
- Conditions
- NAFLD, Overweight and Obesity, Metabolic Syndrome, Diabetes
- Trial name
- LICARB (NCT04581421)
- Testing
- High Carb Low Fat Diet, Low Carb High Fat Diet
- Where
- Denmark
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Hvidovre University Hospital
Non-alcoholic Fatty Liver Disease, Cholesterol Ester Storage Disease
Novel Association of Cholesterol Ester Storage Disease Due to Lysosomal Acid Lipase Deficiency and Non-Alcoholic Fatty Liver Disease: A Prospective Clinical Study
Non-alcoholic fatty liver disease (NAFLD) is a world-wide problem with a global prevalence estimated at 1.5 billion people. It is characterised by significant diversity and phenotypic heterogeneity.
- Trial name
- NCT01791452
- Where
- Israel
- Sponsor
- Assy Nimer
NAFLD (Nonalcoholic Fatty Liver Disease)
Evaluating the Safety and Efficacy of Roflumilast in the Treatment of Nonalcoholic Fatty Liver Disease Patients
Nonalcoholic fatty liver disease (NAFLD) is a global public health concern, and the leading cause of chronic liver disease, especially in developed countries.
- Trial name
- NCT07900087
- Testing
- Roflumilast
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Tanta University
Arthritis, Rheumatoid
Non Alcoholic Fatty Liver Disease in Rheumatoid Arthritis
Rheumatoid arthritis is a chronic inflammatory systemic disease. It has a worldwide distribution and can affect all age group. The peak incidence is between fourth and sixth decade.
- Trial name
- NCT00394238
- Testing
- Ultrasonographic imaging
- Where
- Israel
- Volunteers
- 50 people
- Sponsor
- Shaare Zedek Medical Center
Non-alcoholic Steatohepatitis, Liver Diseases
Reducing Non-Alcoholic Steatohepatitis
The goal of this clinical trial is to learn if empagliflozin works to treat non-alcoholic steatohepatitis in adults. The objectives are: Primary Objective To evaluate the change in histological grading and staging of NASH in…
- Conditions
- Non-alcoholic Steatohepatitis, Liver Diseases, Diabetes Mellitus, Type 2, Fibrosis, Liver
- Trial name
- RedNASH (NCT06519448)
- Testing
- Empagliflozin 10 miligrams (mg)
- Where
- Czechia
- Volunteers
- 30 people
- Sponsor
- Military University Hospital, Prague
NAFLD, Alcoholic Hepatitis
EUS Guided Liver Biopsy - Will it Give Better Yield, More Tissue With Less Complication?
Liver biopsy would be done by Endoscopic Ultrasound using Acquire needle.
- Trial name
- NCT04235855
- Testing
- Endoscopic USG guided Liver biopsy, Percutaneous Liver Biopsy
- Where
- India
- Volunteers
- 50 people
- Sponsor
- Asian Institute of Gastroenterology, India
Non-Alcoholic Fatty Liver Disease, Osteoporosis
Effect of Fatty Liver Disease on Bone Density
Non Alcohlic Fatty Liver (NAFLD) is a spectrum of diseases that ranges from accumulation of fat in the liver (Hepatosteatosis) that may be accompanied by inflammation (Steatohepatitis) to necrosis, fibrosis and even cirrhosis…
- Trial name
- NCT04850547
- Volunteers
- 80 people
- Sponsor
- Sohag University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.